Buy - Gsk Shares

: The payout ratio sits at a healthy 38%–51% of earnings, suggesting the dividend is well-covered by cash flow. ⚠️ The Bear Case: Risks to Watch

: Like many pharma giants, GSK faces major patent expiries toward 2030, putting pressure on the pipeline to deliver blockbuster replacements. buy gsk shares

Investors are "piling into" GSK due to several key shifts in the company's fundamentals: : The payout ratio sits at a healthy

AI responses may include mistakes. For financial advice, consult a professional. Learn more Why is everyone buying GSK shares? | The Motley Fool UK For financial advice, consult a professional

GSK remains a staple for income-seeking investors, with management showing a commitment to increasing payouts:

🎯 : GSK is scheduled to report its Q1 2026 earnings on April 29, 2026 , with analysts expecting revenue of roughly $10.24 billion .